ARTICLE | Clinical News
Amitiza lubiprostone regulatory update
October 11, 2010 7:00 AM UTC
Sucampo submitted an MAA in Japan for Amitiza lubiprostone to treat chronic idiopathic constipation ( CIC). Sucampo and Takeda market the functional fatty acid chloride channel activator in the U.S. ...